Form 4: Intra-Cellular Therapies CFO Lawrence J. Hineline Reports Stock Transaction
SEC Form 4 Filing
Lawrence J. Hineline, SVP of Finance and CFO at Intra-Cellular Therapies, Inc., reports the conversion of restricted stock units into common stock on March 6, 2024.
Summary
- On March 6, 2024, Lawrence J. Hineline, the SVP of Finance and CFO of Intra-Cellular Therapies, Inc., executed a transaction involving restricted stock units.
- Specifically, 13,132 restricted stock units were converted into 13,132 shares of common stock.
- Following this transaction, Hineline directly owns 26,266 derivative securities.
- The restricted stock units were granted on March 6, 2023, and vest in three equal annual installments beginning on the first anniversary of the grant date.
Sentiment
Score: 5
Explanation: This is a neutral report of a standard stock transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/06/2023 | Reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 03/06/2024 | Conversion of 13,132 restricted stock units into common stock. |
| 03/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.